{
    "clinical_study": {
        "@rank": "53485", 
        "arm_group": [
            {
                "arm_group_label": "BIAsp", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Insulin aspart", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This this trial is conducted in Europe. The aim of this trial is to compare glycaemic\n      control of biphasic insulin aspart 30 (BIAsp 30) alone or combined with insulin aspart(IAsp)\n      in patients previously treated with conventional Biphasic Human Insulin 30/70."
        }, 
        "brief_title": "Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes", 
        "completion_date": {
            "#text": "April 2003", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 2 diabetes\n\n          -  Current treatment with conventional biphasic human insulin 30/70 b.i.d. (twice daily)\n             for at least 3 months\n\n          -  HbA1c (glycosylated haemoglobin) equal to or below 12%\n\n          -  Willing and able to perform self blood glucose monitoring (SMBG)\n\n        Exclusion Criteria:\n\n          -  History of drug or alcohol dependence\n\n          -  Mental incapacity, unwillingness or language barriers precluding adequate\n             understanding or co-operation\n\n          -  Previous participation in this trial\n\n          -  Receipt of any investigational drug within the last month prior to this trial\n\n          -  Known or suspected allergy to trial products or related products"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "131", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01697631", 
            "org_study_id": "BIASP-1409"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "BIAsp", 
                    "Insulin aspart"
                ], 
                "description": "Administrated subcutaneously (s.c., under the skin) at breakfast and evening main meals", 
                "intervention_name": "biphasic insulin aspart 30", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Insulin aspart", 
                "description": "Administrated subcutaneously (s.c., under the skin) before lunch", 
                "intervention_name": "insulin aspart", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin aspart", 
                "Insulin", 
                "Insulin, NPH"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "September 28, 2012", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Sosnowiec", 
                    "country": "Poland", 
                    "zip": "41-200"
                }
            }
        }, 
        "location_countries": {
            "country": "Poland"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparison of Biphasic Insulin Aspart 30 Twice Daily and Biphasic Insulin Aspart 30 Twice Daily Plus Lunchtime Injection of Insulin Aspart Treatment Efficiency in Overall Glycemic Control and Postprandial Glycemic Excursions. A Multi-center, Randomized, Open-label, Two-armed Parallel Group Trial in Subjects With Type 2 Diabetes Previously Treated With Conventional Biphasic Human Insulin 30/70", 
        "overall_official": {
            "affiliation": "Novo Nordisk RONAG", 
            "last_name": "Irek Otulski", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Poland: Ministry of Health and Social Security", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2003", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "HbA1c (glycosylated haemoglobin)", 
            "safety_issue": "No"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01697631"
        }, 
        "responsible_party": {
            "name_title": "Public Access to Clinical Trials", 
            "organization": "Novo Nordisk A/S"
        }, 
        "secondary_outcome": [
            {
                "measure": "7-point blood glucose profile", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Correlation of endpoint HbA1c with baseline BMI (body mass index) and HbA1c with treatment mode stratification", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Hypoglycaemic episodes (minor, major or nocturnal)", 
                "safety_issue": "No"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}